Skip to content
SPY$754.37down −0.36%
Nasdaq$679.89down −1.20%
Nvidia$162.85down −2.01%
SpaceX$139.11down −0.59%
VIX20.02up +3.73%
BTC$64,526.00down −0.25%
Gold$3,848.73up +0.75%
Silver$47.70down −1.16%
Brent oil$96.38up +0.09%
DXY103.24up +0.26%
EUR/USD1.1014down −0.07%
USD/JPY159.40down −0.13%
2Y yield4.86%down −1 bp
5Y yield4.98%up +3 bp
10Y yield5.15%up +5 bp

Search FinPrism

Companies · · 3 min read

Editor: Bohdan S.

FDA rejects Summit’s China-invented lung cancer drug ivonescimab

US regulators turned down Summit Therapeutics' ivonescimab, licensed from China's Akeso, because its main trial did not prove patients lived longer. The decision tests faith in Chinese-discovered medicines.

FDA rejects Summit's China-invented lung cancer drug ivonescimab

The short answer

The FDA has declined to approve ivonescimab, a lung cancer drug Summit Therapeutics licensed from China's Akeso, saying slower tumor growth alone was not enough without a clear survival gain. The Financial Times (FT) reported the decision is a blow to China's biotech sector, as the drug was viewed as a test of Chinese medicines in the US.

What happened

Summit Therapeutics (SMMT) said on Sunday that the US Food and Drug Administration had sent it a complete response letter, the formal notice that an application cannot be approved as filed. The request covered ivonescimab plus platinum chemotherapy for advanced non-small cell lung cancer in patients whose disease had progressed after EGFR-targeted pills. The FDA said that without a statistically significant improvement in overall survival, a longer delay in disease progression did not justify approval. The Financial Times (FT) reported that the rejection hurts Beijing's biotech ambitions, since the drug was seen as a test case for whether medicine invented in China could clear US review.

What it means

Ivonescimab is a bispecific antibody, meaning one molecule hits two targets. It blocks PD-1, a protein that lets tumors hide from the immune system, and VEGF, which tumors use to build new blood vessels. Akeso, the Chinese company that discovered it, kept rights in China and some other markets, and the drug has won three lung cancer approvals there. Summit took rights for the US, Canada, Europe and Japan in 2022 in a deal worth up to $5 billion, including $500 million paid upfront, according to pharmaphorum.

The setback was not a complete surprise. In the global Phase 3 HARMONi trial, adding ivonescimab to chemotherapy cut the risk of disease progression or death by 48% versus chemotherapy alone, Reuters reported. But the main survival analysis showed only a positive trend that fell short of statistical significance. Summit filed anyway, pointing to later follow-up data. The company said a post-hoc look, meaning an analysis done after the fact, showed a hazard ratio of 0.76 across the full group, Asian patients and Western patients alike. The FDA held firm that survival must be clearly shown.

Summit also stressed that no FDA-approved regimen in this patient group has yet shown a statistically significant survival benefit. Reuters noted that existing options include Johnson & Johnson's Rybrevant combination and AstraZeneca's Tagrisso.

The bigger question is what happens next. Pharmaphorum said market watchers see the decision as a temporary setback, with attention now on the HARMONi-3 trial, which compares ivonescimab plus chemotherapy with MSD's Keytruda plus chemotherapy as a first treatment. Results for patients with squamous lung cancer could arrive by the end of this year, and data for the non-squamous group are expected in the first half of 2027. AstraZeneca invested $2 billion for a 10% stake in Summit in September and plans combination studies with its own cancer drugs.

The delay may also help rivals in the same drug class catch up. Pharmaphorum listed BioNTech and Bristol Myers Squibb's pumitamig, Pfizer and 3SBio's tivunatamig, AbbVie and RemeGen's ABBV-1480, and an MSD candidate, all in mid- to late-stage testing.

The bull case

Ivonescimab clearly slowed disease progression, and Summit's longer follow-up pointed to a consistent survival trend across regions. The FDA's objection centers on one narrow use, while the bigger HARMONi-3 readout in first-line lung cancer is due soon. AstraZeneca's $2 billion stake signals strong outside confidence, and Akeso already sells the drug in China, so the science is far from written off.

The bear case

The FDA has made clear that survival data, not just slower tumor growth, is the bar, and Summit chose to file without meeting it. That raises the stakes for HARMONi-3 and delays any US revenue. Several large drugmakers have rival PD-1 and VEGF drugs in late testing, so the lost time could erode Summit's lead, and the FT framed the decision as a broader blow to Chinese biotech.

Why it matters

For investors

Summit and Akeso shares could react when trading resumes, and the decision may color how investors value other Chinese-discovered drugs licensed to Western companies. Rival developers of similar dual-target drugs could gain relative ground.

The wider context

Biotech stocks often hinge on a few regulatory decisions, so anyone holding healthcare funds is exposed to outcomes like this one. A single regulatory letter can reset the timeline for a company whose value rests largely on one drug.

Market impact

Asset (ticker)Possible moveTimeframeWhy
Summit Therapeutics (SMMT) ↓ Down Short term The FDA rejection delays US sales of its only major drug and raises pressure on upcoming trial results.
Akeso (9926.HK) ↓ Down Short term Akeso discovered the drug, and a US rejection delays its route into markets outside China.

The FinPrism newsroom's view of how these figures could move, as of . It is general news commentary, not a recommendation to buy, sell or hold anything.

Frequently asked questions

Why did the FDA reject ivonescimab?

The FDA said Summit's application lacked substantial evidence of effectiveness because the HARMONi trial did not show a statistically significant improvement in overall survival. The drug did slow disease progression, but regulators said that benefit alone did not support a favorable balance of benefits and risks for approval.

Who makes ivonescimab?

Ivonescimab was discovered by Chinese drugmaker Akeso, which has it approved in three lung cancer uses in China. US-based Summit Therapeutics licensed rights for the US, Canada, Europe and Japan in 2022 in a deal valued at up to $5 billion. AstraZeneca bought a 10% stake in Summit in September.

What happens next for Summit Therapeutics?

The rejection covers only one narrow use. Attention now turns to HARMONi-3, a trial comparing it with Keytruda in first-line lung cancer, with results for squamous patients possible by the end of the year and non-squamous data expected in the first half of 2027.

Sources: Financial Times, Summit Therapeutics (via Yahoo Finance), STAT, pharmaphorum, Reuters (via ARY News)

How this was made: written with AI assistance from the sources listed above, following our editorial standards.

Back to the latest